Sustainability In The Pharma Industry Statistics 2026

Pharmaceutical sustainability is being reshaped by what customers, regulators, and internal management systems demand—from energy and wastewater performance to transparency and reporting. Across the EU and North America, companies are tightening controls on manufacturing impacts while planning upgrades in treatment and compliance processes. This page organizes key signals on energy use, wastewater and micropollutant reduction, greener materials and packaging, and the technologies that support verification.

Key Takeaways

74% of pharmaceutical manufacturing companies reported experiencing environmental compliance pressure from customers/regulators in 2023
78% of surveyed pharmaceutical executives expect sustainability requirements from customers to increase over the next 3 years (2024 survey result)
14% of pharmaceuticals’ global total final energy use is attributable to manufacturing stages in an LCA-based energy breakdown study for medicines’ supply chains (2021 study finding)
1.7x increase: global demand for green pharmaceutical packaging expected to grow 1.7x by 2030 versus 2023 levels (industry market forecast)
$7.4 billion global environmental services market for healthcare/pharma end use projected by 2030 (forecast figure from industry market research report published 2024)
$20.6 billion forecast global sustainable packaging market in 2030 (market forecast; pharma is a key end-use vertical)
25% lower wastewater chemical oxygen demand (COD) achieved with enzymatic/biological treatment vs conventional treatment in a pharma wastewater treatment pilot study
90% reduction in organics in pharmaceutical wastewater treatment reported in a full-scale activated sludge optimization study (removal efficiency)
98% removal of ethinylestradiol achieved using advanced oxidation (ozonation) in a controlled lab study (pharmaceutical micropollutant)
1.2 billion EUR total estimated EU compliance cost impacts from environmental regulation changes for pharmaceutical manufacturing reported in an EU impact assessment
$120 million in cost savings reported by a major pharma manufacturer after switching to renewable electricity contracts (annual savings figure, company sustainability report data)
€300 million projected capex required for the pharmaceutical sector to upgrade wastewater treatment to meet stricter EU requirements (estimates from policy-related industry analysis)
Directive (EU) 2024/… requires large companies including many pharma firms to report on sustainability under CSRD, covering reporting for financial years starting 1 January 2024
ISO 14001: 370,000+ certificates issued globally as of 2022 (environmental management standard used by pharma for sustainability systems)
GRI Standards are used by 10,000+ organizations globally (most pharma ESG reporters adopt GRI-aligned disclosures for sustainability)

Pharma sustainability pressures are rising fast, with major companies investing in cleaner energy, packaging, and wastewater upgrades.

01 · Category

Industry Trends3 stats

74% of pharmaceutical manufacturing companies reported experiencing environmental compliance pressure from customers/regulators in 2023

78% of surveyed pharmaceutical executives expect sustainability requirements from customers to increase over the next 3 years (2024 survey result)

14% of pharmaceuticals’ global total final energy use is attributable to manufacturing stages in an LCA-based energy breakdown study for medicines’ supply chains (2021 study finding)

Interpretation

Industry Trends Interpretation

As the industry trend toward sustainability intensifies, 78% of pharmaceutical executives expect customer-driven sustainability requirements to rise in the next three years, reinforcing that environmental compliance pressure is already hitting 74% of manufacturers in 2023.

02 · Category

Market Size8 stats

1.7x increase: global demand for green pharmaceutical packaging expected to grow 1.7x by 2030 versus 2023 levels (industry market forecast)

$7.4 billion global environmental services market for healthcare/pharma end use projected by 2030 (forecast figure from industry market research report published 2024)

$20.6 billion forecast global sustainable packaging market in 2030 (market forecast; pharma is a key end-use vertical)

$4.8 billion projected global market size for pharma serialization and track-and-trace solutions by 2029 (used for compliance and waste reduction via digitization)

$6.2 billion global market for sustainable supply chain management software projected by 2032 (includes sustainability/ESG modules adopted by pharma)

$1.3 billion projected market for pharmaceutical waste management services by 2030 (global forecast; includes hazardous waste and wastewater treatment)

$1.0 billion global market for green chemistry catalysts and reagents in 2023 (enabling pharma process greening)

$5.6 billion market size for environmental compliance software in 2023 (used by pharma for reporting/controls)

Interpretation

Market Size Interpretation

By 2030, multiple parts of the pharma sustainability market are scaling rapidly, with green pharmaceutical packaging demand expected to grow 1.7x by 2030 versus 2023 levels and the sustainable packaging market forecast to reach $20.6 billion, signaling strong market-size momentum across sustainable materials and services.

03 · Category

Performance Metrics11 stats

25% lower wastewater chemical oxygen demand (COD) achieved with enzymatic/biological treatment vs conventional treatment in a pharma wastewater treatment pilot study

90% reduction in organics in pharmaceutical wastewater treatment reported in a full-scale activated sludge optimization study (removal efficiency)

98% removal of ethinylestradiol achieved using advanced oxidation (ozonation) in a controlled lab study (pharmaceutical micropollutant)

3.5x improvement in atom economy (from 0.12 to 0.42) in a redesigned API synthesis route reported in a greening-chemistry case study

30% decrease in energy consumption per unit product reported for a pharma facility following installation of industrial heat recovery (measured energy intensity change)

40% reduction in landfill waste volume achieved by pharma packaging redesign and recycling program in a published operational study

50% reduction in water use (m3/ton of product) in a pharma manufacturing water stewardship program reported by a peer-reviewed facility assessment

60% reduction in particulate emissions during API drying reported in a control-technology evaluation study (capture efficiency)

75% increase in biogas yield from anaerobic digestion of pharmaceutical wastewater sludge under optimized co-digestion conditions (percent increase vs baseline)

0.3 kg CO2e per kg API reported as life-cycle climate impact benchmark for a particular synthesis route in a cradle-to-gate LCA paper (scope: production)

95% yield achieved for a green-solvent substitution route in an API process development study (process performance)

Interpretation

Performance Metrics Interpretation

Performance metrics in pharma sustainability show clear, measurable gains, including up to 90% organics reduction, 98% removal of ethinylestradiol, 25% lower COD with biological treatment, and 30% less energy per unit after heat recovery.

Sustainability In IndustrySustainability In The Medical Industry Statistics

04 · Category

Cost Analysis8 stats

1.2 billion EUR total estimated EU compliance cost impacts from environmental regulation changes for pharmaceutical manufacturing reported in an EU impact assessment

$120 million in cost savings reported by a major pharma manufacturer after switching to renewable electricity contracts (annual savings figure, company sustainability report data)

€300 million projected capex required for the pharmaceutical sector to upgrade wastewater treatment to meet stricter EU requirements (estimates from policy-related industry analysis)

35% average reduction in operating costs for pharma facilities adopting ISO 14001 environmental management systems (meta-analysis across industrial sectors including pharma)

2-5% energy-cost reduction potential per site from optimizing compressed air systems (applied to manufacturing energy savings relevant to pharma)

30-50% reduction in chemical costs reported when switching from conventional to membrane-based wastewater treatment for specific pharmaceutical effluents (range from engineering review)

€2.7 billion total EU funding available under Horizon Europe for climate and environmental research relevant to green pharma manufacturing (call/program budget figure)

>$1.0 billion procurement spend by large pharma groups on ESG data and compliance tooling (aggregate spend estimate from vendor market survey)

Interpretation

Cost Analysis Interpretation

From the cost analysis view, the data show that sustainability measures can drive substantial savings while major compliance and upgrade expenses loom, with reported examples like 120 million EUR in annual renewable electricity savings and a 35% operating cost reduction from ISO 14001, contrasted against 1.2 billion EUR in EU compliance cost impacts and a projected 300 million EUR capex for wastewater upgrades.

05 · Category

Regulatory & Reporting5 stats

Directive (EU) 2024/… requires large companies including many pharma firms to report on sustainability under CSRD, covering reporting for financial years starting 1 January 2024

ISO 14001: 370,000+ certificates issued globally as of 2022 (environmental management standard used by pharma for sustainability systems)

GRI Standards are used by 10,000+ organizations globally (most pharma ESG reporters adopt GRI-aligned disclosures for sustainability)

US EPA: 2023 Toxic Release Inventory (TRI) included 22.3 million pounds of on-site releases from pharmaceutical manufacturing NAICS 3254 (reported total by NAICS group)

UK Modern Slavery Act requires large businesses (including many pharma firms) to publish a slavery and human trafficking statement annually; compliance threshold is 36,000 GBP turnover

Interpretation

Regulatory & Reporting Interpretation

As CSRD expands sustainability reporting for large companies across the EU, regulators and frameworks are already shaping practice worldwide with ISO 14001 surpassing 370,000 certificates globally, GRI used by 10,000+ organizations, and even in the US pharma industry reporting environmental impacts with 22.3 million pounds of on-site TRI releases in 2023 while the UK Modern Slavery Act adds an annual human rights disclosure layer for large firms.

06 · Category

Emissions & Targets1 stats

53% of manufacturing sites reported as powered by renewable electricity by 2022 in Merck KGaA’s sustainability reporting (renewable electricity share across manufacturing locations)

Interpretation

Emissions & Targets Interpretation

In the Emissions and Targets category, Merck KGaA’s sustainability reporting shows that by 2022, 53% of its manufacturing sites were powered by renewable electricity, signaling a concrete shift to lower emissions against stated energy and emissions goals.

Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Priyanka Sharma. (2026, February 13). Sustainability In The Pharma Industry Statistics. Gitnux. https://gitnux.org/sustainability-in-the-pharma-industry-statistics

MLA

Priyanka Sharma. "Sustainability In The Pharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sustainability-in-the-pharma-industry-statistics.

Chicago

Priyanka Sharma. 2026. "Sustainability In The Pharma Industry Statistics." Gitnux. https://gitnux.org/sustainability-in-the-pharma-industry-statistics.